Intra-Cellular Therapies Inc. (ITCI) Financials

ITCI Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 728.3 million 136.9 million
2023-09-30 717.7 million 117.0 million
2023-06-30 713.6 million 106.5 million
2023-03-31 722.2 million 94.5 million

ITCI Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -2.1 million 14.9 million
2023-09-30 -25.5 million 14.3 million
2023-06-30 -36.8 million 13.2 million
2023-03-31 -60.1 million 10.4 million

ITCI Net Income

No data available :(

ITCI Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 497.9 million - 16.9 million
2023-09-30 493.0 million - 17.5 million
2023-06-30 512.9 million - 18.0 million
2023-03-31 538.7 million - 18.5 million

ITCI Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 96.3 million
2023-09-30 96.1 million
2023-06-30 95.9 million
2023-03-31 95.1 million

ITCI Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 1000 50.8 million 104.7 million -
2023-09-30 268000 41.6 million 105.2 million -
2023-06-30 - 49.8 million 101.0 million -
2023-03-31 - 38.0 million 98.9 million -

ITCI Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 131.5 million 10.7 million
2023-09-30 125.8 million 9.1 million
2023-06-30 110.1 million 7.2 million
2023-03-31 94.7 million 6.8 million

ITCI

Price: $67

52 week price:
45.50
84.89

Earnings Per Share: -1.46 USD

P/E Ratio: -44.44

Exchange: NMS

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Volume: 307914

Ebitda: -22.8 million

Market Capitalization: 7.3 billion

Links: